UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF‐mutant advanced melanoma treated with first‐line anti‐PD‐1 monotherapies or BRAF/MEK inhibitors in a community‐based oncology setting

Cancer medicine (Malden, MA), 2020-11, Vol.9 (21), p.7863-7878

2020

Volltextzugriff (PDF)

High critical current density and improved irreversibility field in bulk MgB2 made by a scaleable, nanoparticle addition route

Applied physics letters, 2002-09, Vol.81 (11), p.2026-2028

2002

Volltextzugriff (PDF)

VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo

Oncogene, 2009-04, Vol.28 (14), p.1694-1705

2009

Volltextzugriff (PDF)

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

The New England journal of medicine, 2017-10, Vol.377 (14), p.1345-1356

2017

Volltextzugriff (PDF)

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

The New England journal of medicine, 2017-11, Vol.377 (19), p.1824-1835

2017

Volltextzugriff (PDF)

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

The New England journal of medicine, 2019-10, Vol.381 (16), p.1535-1546

2019

Volltextzugriff (PDF)

Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)

Annals of oncology, 2018-10, Vol.29, p.viii735-viii735

2018

Volltextzugriff (PDF)

Stearate Preferentially Induces Apoptosis in Human Breast Cancer Cells

Nutrition and cancer, 2009-01, Vol.61 (5), p.746-753

2009

Volltextzugriff (PDF)

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

The New England journal of medicine, 2015-07, Vol.373 (1), p.23-34

2015

Volltextzugriff (PDF)

Abdominal obesity, insulin resistance, and colon carcinogenesis are increased in mutant mice lacking gastrin gene expression

Cancer, 2005-06, Vol.103 (12), p.2643-2653

2005

Volltextzugriff (PDF)

Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis

BJU international, 2011-10, Vol.108 (8), p.1279-1283

2011

Volltextzugriff (PDF)

Critical fields and critical currents in MgB2

Superconductor science & technology, 2003-02, Vol.16 (2), p.176-182

2003

Volltextzugriff (PDF)

FDG‐PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer

Cancer medicine (Malden, MA), 2013-08, Vol.2 (4), p.545-552

2013

Volltextzugriff (PDF)

Investigation of high-Tc bulk material for its use in resistive superconducting fault current limiters

IEEE transactions on applied superconductivity, 2001-03, Vol.11 (1), p.1960-1963

2001

Volltextzugriff (PDF)

Characterization of BSCCO 2212 bulk material for resistive current limiters

IEEE transactions on applied superconductivity, 2001-03, Vol.11 (1), p.2507-2510

2001

Volltextzugriff (PDF)

Résultats mis à jour d’un essai de phase III sur le nivolumab associé à l’ipilimumab chez des patients atteints de mélanome avancé (CheckMate 067)

Annales de dermatologie et de vénéréologie, 2016-12, Vol.143 (12), p.S213-S214

2016

Volltextzugriff (PDF)

A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma

Annals of oncology, 2016-10, Vol.27, p.vi393-vi393

2016

Volltextzugriff (PDF)

Quench testing of HTS sub-elements for 13 kA and 600 A leads designed to the specifications for the CERN Large Hadron Collider project

IEEE transactions on applied superconductivity, 2000-03, Vol.10 (1), p.1466-1469

2000

Volltextzugriff (PDF)

LBA68_PR5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1310OAdjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Superconducting power link for power transmission and fault current limitation

Physica. C, Superconductivity, 2001-05, Vol.354 (1), p.1-4

2001

Volltextzugriff (PDF)

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma

Drug design, development and therapy, 2013-01, Vol.7 (default), p.519-527

Cowey, C Lance

2013

Volltextzugriff (PDF)

Effective vortex pinning in MgB2 thin films

Superconductor science & technology, 2002-10, Vol.15 (10), p.1392-1397

2002

Volltextzugriff (PDF)

Challenging the standard of care in advanced melanoma: focus on pembrolizumab

Cancer management and research, 2017-01, Vol.9, p.433-442

2017

Volltextzugriff (PDF)

LBA44Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

1 – 25 von 154

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(146)
Mit Volltextzugriff
(141)

Publikationsform

Sprache

Englisch
(145)
Französisch
(9)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF‐mutant advanced melanoma treated with first‐line anti‐PD‐1 monotherapies or BRAF/MEK inhibitors in a community‐based oncology setting

High critical current density and improved irreversibility field in bulk MgB2 made by a scaleable, nanoparticle addition route

VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)

Stearate Preferentially Induces Apoptosis in Human Breast Cancer Cells

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Abdominal obesity, insulin resistance, and colon carcinogenesis are increased in mutant mice lacking gastrin gene expression

Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis

Critical fields and critical currents in MgB2

FDG‐PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer

Investigation of high-Tc bulk material for its use in resistive superconducting fault current limiters

Characterization of BSCCO 2212 bulk material for resistive current limiters

Résultats mis à jour d’un essai de phase III sur le nivolumab associé à l’ipilimumab chez des patients atteints de mélanome avancé (CheckMate 067)

A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma

Quench testing of HTS sub-elements for 13 kA and 600 A leads designed to the specifications for the CERN Large Hadron Collider project

LBA68_PR5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma

1310OAdjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

Superconducting power link for power transmission and fault current limitation

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma

Effective vortex pinning in MgB2 thin films

Challenging the standard of care in advanced melanoma: focus on pembrolizumab

LBA44Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)

Suchergebnisse filtern